Skip to main content
Journal cover image

Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.

Publication ,  Journal Article
Micallef, IN; Stiff, PJ; Nademanee, AP; Maziarz, RT; Horwitz, ME; Stadtmauer, EA; Kaufman, JL; McCarty, JM; Vargo, R; Cheverton, PD; Struijs, M ...
Published in: Biol Blood Marrow Transplant
June 2018

The purpose of this report is to analyze long-term clinical outcomes of patients exposed to plerixafor plus granulocyte colony-stimulating factor (G-CSF) for stem cell mobilization. This was a study of patients with non-Hodgkin lymphoma (NHL; n = 167) and multiple myeloma (MM; n = 163) who were enrolled in the long-term follow-up of 2 pivotal phase III studies (NCT00741325 and NCT00741780) of 240 µg/kg plerixafor plus 10 µg/kg G-CSF, or placebo plus 10 µg/kg G-CSF to mobilize and collect CD34+ cells for autologous hematopoietic stem cell transplantation. Overall survival (OS) and progression-free survival (PFS) were evaluated over a 5-year period following the first dose of plerixafor or placebo. The probability of OS was not significantly different in patients with NHL or MM treated with plerixafor or placebo (NHL: 64%; 95% confidence interval [CI], 56% to 71% versus 56%; 95% CI, 44% to 67%, respectively; MM: 64%; 95% CI, 54% to 72% versus 64%; 95% CI, 53% to 73%, respectively). In addition, there was no statistically significant difference in the probability of PFS over 5 years between treatment groups in patients with NHL (50%; 95% CI, 44% to 67% for plerixafor versus 43%; 95% CI, 31% to 54% for placebo) or those with MM (17%; 95% CI, 10% to 24% for plerixafor versus 30%; 95% CI, 21% to 40% for placebo). In this long-term follow-up study, the addition of plerixafor to G-CSF for stem cell mobilization did not affect 5-year survival in patients with NHL or patients with MM.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Biol Blood Marrow Transplant

DOI

EISSN

1523-6536

Publication Date

June 2018

Volume

24

Issue

6

Start / End Page

1187 / 1195

Location

United States

Related Subject Headings

  • Young Adult
  • Transplantation, Autologous
  • Survival Analysis
  • Multiple Myeloma
  • Middle Aged
  • Lymphoma, Non-Hodgkin
  • Longitudinal Studies
  • Immunology
  • Humans
  • Heterocyclic Compounds
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Micallef, I. N., Stiff, P. J., Nademanee, A. P., Maziarz, R. T., Horwitz, M. E., Stadtmauer, E. A., … DiPersio, J. F. (2018). Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report. Biol Blood Marrow Transplant, 24(6), 1187–1195. https://doi.org/10.1016/j.bbmt.2018.01.039
Micallef, Ivana N., Patrick J. Stiff, Auayporn P. Nademanee, Richard T. Maziarz, Mitchell E. Horwitz, Edward A. Stadtmauer, Jonathan L. Kaufman, et al. “Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.Biol Blood Marrow Transplant 24, no. 6 (June 2018): 1187–95. https://doi.org/10.1016/j.bbmt.2018.01.039.
Micallef IN, Stiff PJ, Nademanee AP, Maziarz RT, Horwitz ME, Stadtmauer EA, et al. Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report. Biol Blood Marrow Transplant. 2018 Jun;24(6):1187–95.
Micallef, Ivana N., et al. “Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.Biol Blood Marrow Transplant, vol. 24, no. 6, June 2018, pp. 1187–95. Pubmed, doi:10.1016/j.bbmt.2018.01.039.
Micallef IN, Stiff PJ, Nademanee AP, Maziarz RT, Horwitz ME, Stadtmauer EA, Kaufman JL, McCarty JM, Vargo R, Cheverton PD, Struijs M, Bolwell B, DiPersio JF. Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report. Biol Blood Marrow Transplant. 2018 Jun;24(6):1187–1195.
Journal cover image

Published In

Biol Blood Marrow Transplant

DOI

EISSN

1523-6536

Publication Date

June 2018

Volume

24

Issue

6

Start / End Page

1187 / 1195

Location

United States

Related Subject Headings

  • Young Adult
  • Transplantation, Autologous
  • Survival Analysis
  • Multiple Myeloma
  • Middle Aged
  • Lymphoma, Non-Hodgkin
  • Longitudinal Studies
  • Immunology
  • Humans
  • Heterocyclic Compounds